top of page
News, Events and Updates
Search
Sep 2, 2014
Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Aug 25, 2014
Anavex Selects The Alfred Hospital in Melbourne, Australia as Lead Site for Phase 2a Clinical Trial
Aug 18, 2014
Anavex Reports That Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor
Aug 12, 2014
Anavex Reports Fiscal Third Quarter 2014 Financial Results
Aug 6, 2014
Anavex Appoints Experienced Pharma Executive as Vice President of Clinical Operations
Jul 20, 2014
Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
Jul 16, 2014
Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor
Jul 13, 2014
ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks
Jun 29, 2014
Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
Jun 9, 2014
M1 Muscarinic Agonists and a Multipotent Activator of Sigma1/M1 Muscarinic Receptors
Jun 3, 2014
Anavex Awarded New U.S. Patent
36
37
38
39
40
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
